ATLANTA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel.
| Presentation Date: | Monday, September 11, 2023 |
| Time: | 11:30am ET |
Mr. Eiswirth and Mr. Russell Skibsted, Chief Financial Officer, will be available for one-on-one meetings with investors who are registered to attend the conference. To request a meeting and to register for the conference, please click here: https://hcwevents.com/annualconference/
About Alimera Sciences, Inc.
Alimera Sciences a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit: www.alimerasciences.com
| For investor inquiries: | For media inquiries: |
| Scott Gordon | Jules Abraham |
| for Alimera Sciences | for Alimera Sciences |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$5.54 |
| Daily Volume: | 0 |
| Market Cap: | US$301.270M |
August 06, 2024 May 14, 2024 March 19, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
